RIVERSIDE REGIONAL MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Newport News, VA
- Medicare CCN
- 490052
- Received
- $132,385 in 106 records, 2023 ($15,818 general, $116,566 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 17 | $15,818 |
| 2023 | Research payment | 89 | $116,566 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Roche Products Limited | 75 | $26,300 | 2023 |
| PFIZER INC. | 1 | $19,750 | 2023 |
| Boehringer Ingelheim International GmbH | 1 | $18,013 | 2023 |
| Sage Therapeutics, LLC | 1 | $16,000 | 2023 |
| American Regent | 4 | $14,356 | 2023 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | 1 | $9,759 | 2023 |
| Biogen, Inc. | 1 | $8,458 | 2023 |
| Agfa HealthCare Corporation | 1 | $5,430 | 2023 |
| Philips North America LLC | 3 | $2,880 | 2023 |
| Tandem Diabetes Care, Inc. | 8 | $2,700 | 2023 |
| Penumbra, Inc. | 3 | $2,050 | 2023 |
| Genentech USA, Inc. | 2 | $2,000 | 2023 |
| Stryker Corporation | 1 | $1,433 | 2023 |
| Chiesi USA, Inc. | 1 | $1,000 | 2023 |
| AstraZeneca Pharmaceuticals LP | 1 | $1,000 | 2023 |
| KCI USA, Inc. | 1 | $995 | 2023 |
| B. Braun Medical Inc. | 1 | $259 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 89 | $116,566 |
| Gift | 1 | $5,430 |
| Space rental or facility fees (teaching hospital only) | 4 | $4,000 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 8 | $2,700 |
| Long term medical supply or device loan | 2 | $2,428 |
| Education | 1 | $1,000 |
| Debt forgiveness | 1 | $259 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Stryker Corporation | $1,433 | Long term medical supply or device loan | In-kind items and services | TRURIZE Device, PATIENT CARE - PC | 2023 | |
| 2023-12-27 | Agfa HealthCare Corporation | $5,430 | Gift | Cash or cash equivalent | HP BLc 10Gb SR SFP+ Optical for 6120XG Device, Hardware | 2023 | |
| 2023-12-13 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-12-13 | Roche Products Limited | $300 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-12-04 | Penumbra, Inc. | $750 | Research payment | Cash or cash equivalent | Smart Coil Device, Neurointervention | SURF | 2023 |
| 2023-10-16 | Philips North America LLC | $715 | Research payment | In-kind items and services | (V016) Eagle Eye Platinum Device, Medical Device | IMPROVE RCT | 2023 |
| 2023-10-11 | Philips North America LLC | $715 | Research payment | In-kind items and services | (V016) Eagle Eye Platinum Device, Medical Device | IMPROVE RCT | 2023 |
| 2023-10-04 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-09-27 | Philips North America LLC | $1,450 | Research payment | In-kind items and services | (V016) Eagle Eye Platinum Device, Medical Device | IMPROVE RCT | 2023 |
| 2023-09-22 | PFIZER INC. | $19,750 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGRO | 2023 | |
| 2023-09-22 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-09-22 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-09-22 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-09-22 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-09-07 | Sage Therapeutics, LLC | $16,000 | Research payment | Cash or cash equivalent | Junonia | 2023 | |
| 2023-09-06 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-09-06 | Roche Products Limited | $300 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-09 | Tandem Diabetes Care, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-08-09 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-09 | Roche Products Limited | $150 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-08-02 | Roche Products Limited | $330 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-26 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-07-12 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-06-15 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-06-14 | American Regent | $1,250 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2023 |
| 2023-06-09 | B. Braun Medical Inc. | $259 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-06-07 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-05-30 | Genentech USA, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-05-05 | Chiesi USA, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CLEVIPREX Drug, CARDIOVASCULAR | 2023 | |
| 2023-05-05 | Penumbra, Inc. | $300 | Research payment | Cash or cash equivalent | Smart Coil Device, Neurointervention | SURF | 2023 |
| 2023-04-24 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, Rare Disease | 2023 | |
| 2023-03-23 | Penumbra, Inc. | $1,000 | Education | Cash or cash equivalent | 2023 | ||
| 2023-03-22 | Genentech USA, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2023 | |
| 2023-03-22 | Roche Products Limited | $300 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-03-06 | American Regent | $564 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2023 |
| 2023-02-03 | American Regent | $376 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2023 |
| 2023-01-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $9,759 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death afte | 2023 |
| 2023-01-25 | Biogen, Inc. | $8,458 | Research payment | Cash or cash equivalent | VUMERITY Drug, Neurology | A PROSPECTIVE, OBSERVATIONAL STUDY EVALUATING PERSISTENCE ON TREATMENT, SAFETY, TOLERABILITY, AND EFFECTIVENESS OF DIROX | 2023 |
| 2023-01-19 | American Regent | $12,166 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2023 |
| 2023-01-11 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-04 | Roche Products Limited | $356 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2023 |
| 2023-01-03 | Boehringer Ingelheim International GmbH | $18,013 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin for prevention of HHF and death afte | 2023 |
| 2023-01-01 | KCI USA, Inc. | $995 | Long term medical supply or device loan | Cash or cash equivalent | ATTEST Device, Sterilizers & Sterilization Indicators | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Newport News, VA, county Newport News city, VA, state Virginia; placed by its city name.
| Measure | Place (city or town) Newport News, VA | County Newport News city, VA | State Virginia |
|---|---|---|---|
| Population B01003 | 184,216 | 184,216 | 8,705,170 |
| Population, 2020 census P1 | 186,247 | 186,247 | 8,631,393 |
| Median age B01002 | 34.4 | 34.4 | 39.0 |
| Under 18 B01001 | 23.2% | 23.2% | 21.7% |
| 65 and over B01001 | 14.1% | 14.1% | 16.7% |
| Households B11001 | 76,112 | 76,112 | 3,365,732 |
| Foreign born B05002 | 7.7% | 7.7% | 13.1% |
| Median household income B19013 | $69,634 | $69,634 | $93,170 |
| Median family income B19113 | $85,499 | $85,499 | $115,213 |
| Per capita income B19301 | $38,773 | $38,773 | $50,666 |
| Poverty rate B17001 | 14.5% | 14.5% | 9.9% |
| Unemployment rate B23025 | 5.8% | 5.8% | 4.3% |
| Civilian labor force B23025 | 89,628 | 89,628 | 4,468,236 |
| Mean commute (minutes) B08013 | 23.1 | 23.1 | 27.3 |
| Bachelor's degree or higher B15003 | 30.6% | 30.6% | 42.2% |
| Housing units B25001 | 82,052 | 82,052 | 3,684,756 |
| Owner-occupied B25003 | 48.2% | 48.2% | 67.3% |
| Renters B25003 | 51.8% | 51.8% | 32.7% |
| Median home value B25077 | $260,600 | $260,600 | $383,700 |
| Median gross rent B25064 | $1,339 | $1,339 | $1,579 |
| White, not Hispanic B03002 | 39.2% | 39.2% | 58.4% |
| Black B03002 | 40.6% | 40.6% | 18.3% |
| Hispanic or Latino B03002 | 10.8% | 10.8% | 11.0% |
| Asian B03002 | 3.3% | 3.3% | 6.9% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Newport News, VA.
Comments